Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
Not Applicable
Completed
- Conditions
- Esophageal CarcinomaPeritoneal CancerGastrointestinal CarcinomaLung CancerFallopian Tube CancerOvarian CancerPancreatic CarcinomaEndometrial Cancer
- Interventions
- Other: Narrow Band Imaging (NBI)
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 154
- Registration Number
- NCT01262040
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events
Completed
- Conditions
- High Risk for Postoperative Cardiovascular Events
- Interventions
- Other: endothelial function testing
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT01262222
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT01261728
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Hartford Hospital (Data Collection Only), Hartford, Connecticut, United States
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01259063
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation
Terminated
- Conditions
- FibrillationPost-Operative Cancer Patients Experiencing Atrial
- Interventions
- Behavioral: questionnaire about the use of ECG device
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT01253590
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Phase 2
Completed
- Conditions
- Uveal Melanoma
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT01252251
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Not Applicable
Terminated
- Conditions
- Breast Cancer
- Interventions
- Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01249157
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Fallopian Tube CancerPeritoneal CancerOvarian Cancer
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 146
- Registration Number
- NCT01248962
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
Phase 1
Completed
- Conditions
- Peritoneal CancerOvarian CancerFallopian Tubes
- Interventions
- Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01248273
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
Terminated
- Conditions
- Breast Cancer
- Interventions
- Other: GlowCap device
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01239251
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States